UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 10-Q
(Mark One)
[X] Quarterly report pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
For the period ended December 31, 1996
OR
[ ] Transition report pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
Commission File Number: 0-13588
FAULDING INC.
(Exact name of registrant as specified in its charter)
Delaware 04-2769995
(State of other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification No.)
200 Elmora Avenue
Elizabeth, NJ 07207
(Address of principal executive office)
Telephone Number (908) 527-9100
(Registrant's telephone number, including area code)
Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act
of 1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to
such filing requirements for the past 90 days: Yes [X] No [ ]
As of February 6, 1997, there were 15,068,060 shares of the Registrant's
Common Stock outstanding.
<PAGE>
Faulding Inc.
INDEX
Page No.
PART I - FINANCIAL INFORMATION
ITEM 1. Consolidated Financial Statements:
Consolidated Balance Sheets
December 31, 1996 and June 30, 1996 . . . . . . . . 3
Consolidated Statements of Operations
Three months ended December 31, 1996
and 1995 and six months ended
December 31, 1996 and 1995 . . . .. . . . . . . . . . 4
Consolidated Statements of Cash Flows
Six months ended December 31, 1996
and 1995 . . . . . . . . . . .. . . . . . . . . . . 5
Notes to Consolidated Financial Statements . . . . . 6
ITEM 2. Management's Discussion and Analysis of
Financial Condition and Results of Operations . . . 10
PART II - OTHER INFORMATION
ITEMS 1 thru 6 . . . . . . . . . . .. . . . . . . . . . . . . 15
SIGNATURES . . . . . . . . . . . . . . . . . . . . . . . . . 16
2
<PAGE>
CONSOLIDATED BALANCE SHEETS
(Dollars in thousands, except per share amounts)
December 31, June 30,
1996 1996
(Unaudited) (Audited)
- --------------------------------------------------------------------------
ASSETS
- --------------------------------------------------------------------------
CURRENT ASSETS:
Cash and cash equivalents $ 3,007 $ 1,897
Accounts receivable 14,617 17,118
Inventory (Note 4) 28,417 26,496
Due from affiliated companies 537 ---
Other current assets 3,266 3,315
Deferred income taxes (Note 6) 2,062 3,225
- --------------------------------------------------------------------------
TOTAL CURRENT ASSETS 51,906 52,051
- --------------------------------------------------------------------------
Property, plant and equipment, net 43,767 41,510
Other assets 4,171 4,279
Deferred income taxes (Note 6) 1,914 838
- --------------------------------------------------------------------------
TOTAL ASSETS $ 101,758 $ 98,678
==========================================================================
LIABILITIES AND STOCKHOLDERS' EQUITY
- --------------------------------------------------------------------------
CURRENT LIABILITIES:
Accounts payable $ 6,342 $ 7,553
Due to affiliated companies --- 847
Loan payable to bank 7,000 ---
Accrued expenses 5,965 6,666
Accrued preferred dividends 689 689
- --------------------------------------------------------------------------
TOTAL CURRENT LIABILITIES 19,996 15,755
- --------------------------------------------------------------------------
STOCKHOLDERS' EQUITY (Note 1 and 2)
Class A convertible preferred stock;
par value $.01, authorized 1,834,188
shares; issued and outstanding 834,188
(liquidation value $24,995,171) 8 8
Class B convertible preferred stock;
par value $.01, authorized 150,000
shares; issued and outstanding 150,000
(liquidation value $15,169) 2 2
Common stock; par value $.01, authorized
35,000,000 shares; issued and outstanding
15,064,560 at December 31, 1996 and June
30, 1996 151 151
Capital in excess of par value 55,865 57,138
Retained earnings 25,736 25,624
- --------------------------------------------------------------------------
TOTAL STOCKHOLDERS' EQUITY 81,762 82,923
- --------------------------------------------------------------------------
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $ 101,758 $ 98,678
==========================================================================
The accompanying notes are an integral part of these consolidated financial
statements.
3
<PAGE>
<TABLE>
<CAPTION>
CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)
(Dollars in thousands, except per share amounts)
Three Months Ended Six Months Ended
December 31, December 31,
------------------------- -------------------------
1996 1995 1996 1995
- ----------------------------------------------------------------------------------------------------------------
<S> <C> <C> <C> <C>
NET SALES $ 22,229 $ 18,126 $ 40,814 $ 33,698
Cost of sales 16,679 14,358 29,692 28,076
- ----------------------------------------------------------------------------------------------------------------
Gross profit 5,550 3,768 11,122 5,622
- ----------------------------------------------------------------------------------------------------------------
Expenses:
Selling, general and administrative 3,389 2,651 6,420 5,504
Research and development 1,914 2,863 4,402 5,093
Restructuring costs --- 579 --- 579
- ----------------------------------------------------------------------------------------------------------------
Total expenses 5,303 6,093 10,822 11,176
- ----------------------------------------------------------------------------------------------------------------
Income (loss) form operations 247 (2,325) 300 (5,554)
Other income (expense), net (94) 1,466 (113) 1,187
- ----------------------------------------------------------------------------------------------------------------
Income (loss) before income taxes 153 (859) 187 (4,367)
Provision (benefit) for income taxes (Note 6) 75 (157) 75 (815)
- ----------------------------------------------------------------------------------------------------------------
Income (loss) Before Preferred Stock Dividends 78 (702) 112 (3,552)
Preferred stock dividends 689 520 1,378 1,040
- ----------------------------------------------------------------------------------------------------------------
NET INCOME (LOSS), AVAILABLE FOR COMMON STOCK $ (611) $ (1,222) $ (1,266) $ (4,592)
================================================================================================================
Primary Earnings Per Common Share (Note 3)
Net income (loss) $ (0.04) $ (0.08) $ (0.08) $ (0.03)
- ----------------------------------------------------------------------------------------------------------------
Weighted average number of common shares outstanding 15,064,560 15,018,935 15,064,560 15,018,935
================================================================================================================
The accompanying notes are an integral part of these consolidated financial
statements.
</TABLE>
4
<PAGE>
CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)
(Dollars in thousands)
Six Months Ended
December 31,
-----------------------------
1996 1995
- -----------------------------------------------------------------------------
CASH FLOWS FROM OPERATING ACTIVITIES:
Net Income (Loss), Available for Common Stock $ (1,266) $ (4,592)
Adjustments To Reconcile Net Income (Loss)
to Net Cash
Provided By (Used For) Operating Activities:
Depreciation and amortization 1,884 1,513
Compensation expense-stock grants 162 103
Deferred income tax, asset 87 165
INCREASE (DECREASE) IN CASH FROM:
Accounts receivable 2,501 (545)
Inventory (1,921) (1,898)
Other current assets --- (1,541)
Other assets (43) (1,210)
Accounts payable (1,211) 1,653
Accrued expenses (701) 785
Accrued income taxes (10) (980)
Due to/from affiliates (1,383) 1,671
- -----------------------------------------------------------------------------
TOTAL ADJUSTMENTS (635) (284)
- -----------------------------------------------------------------------------
Net Cash Provided By (Used For)
Operating Activites (1,901) (4,876)
- -----------------------------------------------------------------------------
CASH FLOWS FROM INVESTING ACTIVITES:
Purchases of property, plant and equipment (3,989) (1,301)
- -----------------------------------------------------------------------------
Net Cash Provided By (Used For)
Investing Activities (3,989) (1,301)
- -----------------------------------------------------------------------------
CASH FLOWS FROM FINANCING ACTIVITES:
Borrowings from bank 7,000 3,000
Proceeds from additions to paid in capital --- 2,906
- -----------------------------------------------------------------------------
Net Cash Provided By (Used For)
Financing Activites 7,000 5,906
- -----------------------------------------------------------------------------
Increase (Decrease) In Cash and Cash Equivalents $ 1,110 $ (271)
=============================================================================
Cash and cash equivalents,
beginning of period 1,897 1,225
- -----------------------------------------------------------------------------
Cash and cash equivalents,
end of period $ 3,007 $ 954
=============================================================================
Supplemental disclosure of cash flow information:
Cash paid (received) during the period for:
Interest $ 123 $ 64
Income Taxes $ --- $ ---
- -----------------------------------------------------------------------------
The accompanying notes are an integral part of these consolidated financial
statements.
5
<PAGE>
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
(Dollars in Thousands)
Notes to the Financial Statements included in Faulding Inc.'s (the "Company")
Form 10-K for the year ended June 30, 1996 contain information pertinent to
the accompanying financial statements and should be read in conjunction with
reading these financial statements. There has been no material change in the
information contained in such footnotes except as set forth below. The
Consolidated Balance Sheet at December 31, 1996, the Consolidated Statements
of Operations for the three and six months ended December 31, 1996 and 1995
and the Consolidated Statements of Cash Flows for the six months ended
December 31, 1996 and 1995 are unaudited.
In the opinion of management, all adjustments (consisting only of normal
recurring entries) necessary for a fair presentation of such financial
results have been included.
1. Acquisitions and Consolidation
On February 29, 1996 the Company acquired all of the outstanding
capital stock of each of Faulding Medical Device Co. ("FMD"),
Faulding Puerto Rico, Inc. ("FPR"), and Faulding Pharmaceutical Co.
("FPC"), collectively the "Acquired Companies," from Faulding
Holdings Inc. (the Company's principal stockholder) in exchange
for 2,438,712 shares of its common stock. As part of the
acquisition, the Company created a Class B Preferred Stock with
150,000 authorized shares, par value at $.01, all of which were
issued to Faulding Holdings Inc. for a cash purchase price of $100
per share, for a total value of $15 million.
The acquisition transaction was accounted for as similar to a pooling
of interests and, therefore, financial statements for the six months
ended December 31, 1995 have been restated as if the acquisition
took place at the beginning of the earliest period presented. The
financial statements reflect the accounts of Faulding Inc. (including
its wholly owned subsidiary, Purepac Pharmaceutical Co.) and the
Acquired Companies. All intercompany transactions and balances have
been eliminated.
6
<PAGE>
2. A reconciliation of the change in total stockholders' equity
is as follows:
Par
Value of
Common and Capital in Total Stock
Preferred Excess of Retained -holders'
Stock Par Value Earnings Equity
---------- ----------- ---------- ----------
Balance, June 30, 1996 $ 161 $ 57,138 $ 25,624 $ 82,923
Class A preferred
stock dividend (1,040) (1,040)
Class B preferred
stock dividend (338) (338)
Stock grant amortization 162 162
Reduction of deferred
income tax asset from
issuance of stock grants (57) (57)
Net Income 112 112
---------- ----------- ---------- ----------
Balance, December 31, 1996 $ 161 $ 55,865 $ 25,736 $ 81,762
========== =========== ========== ==========
3. Earnings Per Common Share
Primary earnings per common share is calculated by dividing
income after preferred dividends by the weighted average
number of common shares outstanding during the period.
Common stock equivalents are excluded as the effect is
anti-dilutive. Earnings per share assuming full dilution is
not presented as the effect would be anti-dilutive.
4. Inventory
December 31, June 30,
1996 1996
---------- ----------
Raw materials $ 9,400 $ 11,160
Work-in-progress 7,405 4,509
Finished goods 11,612 10,827
---------- ----------
Total $ 28,417 $ 26,496
========== ==========
5. Capital Stock
During the quarter ended December 31, 1996 no additional
shares were issued.
6. Accounting for Income Taxes
Deferred income tax assets, both current and non-current,
reflect the net tax effects of (a) temporary differences
between the carrying amounts of assets and liabilities for
financial reporting purposes and the amounts used for income
tax purposes, and (b) operating loss and tax credit
carryforwards.
7
<PAGE>
The income tax expense provision does not include the benefit
of recognizing available loss carryforwards to the extent
they have already been recognized as a deferred tax asset.
Instead, there is a reduction in the deferred tax asset as
such benefits are utilized to reduce taxes payable.
The provision (benefit) for income tax expense was comprised
of the following:
Three Months Ended Six Months Ended
December 31, December 31,
---------------------- ----------------------
1996 1995 1996 1995
---------- --------- ---------- ---------
Current
Federal $ 68 $ (132) $ 68 $ (665)
State 11 --- 11 (63)
---------- --------- ---------- ---------
79 (132) 79 (728)
Deferred
Federal (4) --- (4) (24)
State --- (25) --- (63)
---------- --------- ---------- ---------
Total provisions $ 75 $ (157) $ 75 $ (815)
========== ========= ========== =========
The Company has net operating losses and tax credits available as
carryforwards to reduce future payments of federal income taxes.
State tax losses are also available as carryforwards. At December
31, 1996, for federal tax purposes, the net operating loss and tax
credit carryforwards amounted to $14,870 and $707, respectively; they
expire through year 2003. The future utilization of the net
operating loss carryforwards is subject to limitation under
provisions of the Internal Revenue Code.
The benefit of net operating losses generated by the Acquired
Companies prior to acquisition by the Company cannot be realized
until the individual company generates taxable income to utilize
such benefit. As of December 31, 1996 this had not occurred, and a
full valuation allowance has been provided for these net operating
losses.
7. New Accounting Pronouncements
In October 1995, the Financial Accounting Standards Board issued
Statement of Financial Accounting Standard No. 123 "Accounting For
Stock Based Compensation" ("SFAS 123") which requires that an
employer's financial statements include expanded disclosure regarding
stock-based employee compensation arrangements. The Company will
adopt the disclosure only requirements of SFAS 123, therefore, such
adoption will have no effect on the Company's consolidated financial
condition or results of operations.
8
<PAGE>
In March 1995, the Financial Accounting Standards Board issued
Statement of Financial Accounting Standard No. 121 "Accounting For
The Impairment Of Long-Lived Assets" ("SFAS 121") which requires that
long-lived assets be reviewed for impairment whenever events or
changes in circumstance indicate that the carrying amount of an
asset may not be recoverable. To determine a loss, if any, to be
recognized, the book value of the asset would be compared to the
market value or expected future cash flow value. The Company is
adopting SFAS 121 for the fiscal year ended June 30, 1997 and
anticipates, based upon information currently available, that it
will not have a material impact on its results of operations and
financial position.
9
<PAGE>
Item 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS
(Dollars presented in thousands)
Results Of Operations - Three and Six Month Periods Ended December 31, 1996
Compared with the Three and Six Month Periods Ended December 31, 1995
Overview: Acquisitions and Consolidation
On February 29, 1996 the Company acquired all of the outstanding capital
stock of each of Faulding Medical Device Co. ("FMD"), Faulding Puerto Rico,
Inc. ("FPR"), and Faulding Pharmaceutical Co. ("FPC"), collectively the
"Acquired Companies," from Faulding Holdings Inc. (the Company's majority
stockholder) in exchange for 2,438,712 shares of its common stock. As a
result, the acquisition transaction was accounted for as similar to a
pooling of interests and, therefore, financial statements for the three and
six month periods ended December 31, 1995 have been restated as if the
acquisition took place at the beginning of the earliest period presented.
The financial statements reflect the accounts of Faulding Inc. (including
its wholly owned subsidiary, Purepac Pharmaceutical Co.) and the Acquired
Companies.
Results of Operations
The following segregates the results of operations before income taxes for
Faulding Inc. into the Company's business prior to the acquisition,
"Purepac," and the Acquired Companies which became wholly owned subsidiaries
of Faulding Inc. effective March 1, 1996.
<TABLE>
<CAPTION>
STATEMENTS OF OPERATIONS (UNAUDITED) - Purepac
Three Months Ended Six Months Ended
December 31, December 31,
------------------------- -------------------------
1996 1995 1996 1995
- ----------------------------------------------------------------------------------------------------------------
<S> <C> <C> <C> <C>
NET SALES $ 19,400 $ 14,522 $ 35,578 $ 28,689
Cost of sales 13,329 11,457 23,494 23,112
- ----------------------------------------------------------------------------------------------------------------
Gross profit 6,071 3,065 12,084 5,577
- ----------------------------------------------------------------------------------------------------------------
Expenses:
Selling, general and administrative 2,818 1,980 5,255 4,235
Research and development 1,596 2,596 3,541 4,547
Restructuring costs --- 579 --- 579
- ----------------------------------------------------------------------------------------------------------------
Total Expenses 4,414 5,155 8,796 9,361
- ----------------------------------------------------------------------------------------------------------------
Income (loss) form operations 1,657 (2,090) 3,288 (3,784)
Other income (expense), net (94) 1,681 (113) 1,640
- ----------------------------------------------------------------------------------------------------------------
Income (loss) before income taxes 1,563 (409) 3,175 (2,144)
- ----------------------------------------------------------------------------------------------------------------
</TABLE>
10
<PAGE>
<TABLE>
<CAPTION>
STATEMENTS OF OPERATIONS (UNAUDITED) - Acquired Companies
Three Months Ended Six Months Ended
December 31, December 31,
------------------------- -------------------------
1996 1995 1996 1995
- ----------------------------------------------------------------------------------------------------------------
<S> <C> <C> <C> <C>
NET SALES $ 2,829 $ 3,604 $ 5,236 $ 5,009
Cost of sales 3,350 2,900 6,198 4,964
- ----------------------------------------------------------------------------------------------------------------
Gross profit (521) 704 (962) 45
- ----------------------------------------------------------------------------------------------------------------
Expenses:
Selling, general and administrative 572 671 1,165 1,268
Research and development 317 267 861 547
- ----------------------------------------------------------------------------------------------------------------
Total Expenses 889 938 2,026 1,815
- ----------------------------------------------------------------------------------------------------------------
Income (loss) form operations (1,410) (234) (2,988) (1,770)
Other income (expense), net --- (215) --- (453
- ----------------------------------------------------------------------------------------------------------------
Income (loss) before income taxes (1,410) (449) (2,988) (2,223)
- ----------------------------------------------------------------------------------------------------------------
</TABLE>
The discussion below relates to the segregated results presented above.
Purepac Results of Operations
Net sales for the three and six month periods ended December 31, 1996 were
$19,400 and $35,578, respectively, compared with $14,522 and $28,689 for the
corresponding 1995 periods. The increase is primarily due to sales of
diclofenac, which was approved by the United States Food and Drug
Administration ( FDA") and commercialized in March 1996. Diclofenac sales
represented 27% and 25% of the net sales for the current three and six month
periods, respectively. In addition to diclofenac, sales of indapamide and
diflunisal, which were both approved by the FDA and commercialized in the
quarter ended June 30, 1996 and sales related to the contract manufacturing
of KADIAN(TM) for Faulding Services Inc. were recorded in the current three and
six month periods. Faulding Services Inc. is a wholly-owned subsidiary of
Faulding Holdings Inc.
Gross profit for the three and six month periods ended December 31, 1996
were $6,071 and $12,084, respectively, compared with $3,065 and $5,577 for
the corresponding 1995 periods. Gross profit as a percentage of net sales
for the current three and six month periods were 31% and 34%, respectively,
compared with 21% and 19% for the corresponding periods in the prior year.
The increase was mostly attributable to the sales of diclofenac and
indapamide plus contract manufacturing of KADIAN(TM).
Selling, general and administrative expenses for the current three and six
month periods were $2,818 and $5,255, respectively, compared with the
corresponding prior period's respective amounts of $1,980 and $4,235.
Current periods' expenses as a percentage of net sales were both 15% compared
with 14% and 15% for the corresponding prior year's periods. The increase
in the expense
11
<PAGE>
level for the current three month period was due to higher personnel and
promotion expenses as well as an increase in the bad debt provision to
provide for a customer who filed for protection under Chapter 11 of the U.S.
Bankruptcy Code.
Research and development expenses for the current three and six month periods
were $1,596 and $3,541, respectively, compared with $2,596 and $4,547 for the
corresponding 1995 periods. The current period's expense as a percent of
net sales were 8% and 10%, respectively, compared with 18% and 16% for the
corresponding prior periods. While the Company is continuing expenditures
for product development and associated biostudies, the reduced expenses in
the current period reflects mostly timing differences associated with
biostudy scheduling.
In the three and six month periods ended December 1995, the Company incurred
$579 in restructuring costs primarily relating to severance arrangements.
No such costs have been incurred in the current year.
The other income (expense) reflects interest expense and revolving credit
agreement fees versus interest income. Other income (expense) for the
current three and six month periods were ($94) and ($113), respectively,
compared with $1,681 and $1,640 in the prior year's corresponding periods.
The prior year's periods increase in other income versus the current year is
primarily attributable to the settlement of a patent litigation by Purepac
which was recorded in the quarter ended December 31, 1995.
Income before income taxes for the current three and six month periods were
$1,563 and $3,175, respectively, compared with a net loss before income taxes
of $409 and $2,144 for the corresponding 1995 periods.
The results for the three and six month periods ended December 31, 1996 were
positively affected by the commercialization of new product approvals for
diclofenac, indapamide and income resulting from contract manufacturing of
KADIAN(TM), partly offset by negative pricing pressures within the oral generic
pharmaceutical industry. The future financial results will continue to be
highly dependent on the ability of income from sales of new products to
counter ongoing price erosion within the industry.
Acquired Companies Results of Operations
The Acquired Companies became wholly owned subsidiaries of Faulding Inc.
effective March 1, 1996.
Net sales for the three and six month periods ended December 31, 1996 were
$2,829 and $5,236, respectively, compared with $3,604 and $5,009 for the
corresponding 1995 periods. Products manufactured at the FPR production
facility in Aguadilla, Puerto Rico represented 62% and 60% of the net sales for
12
<PAGE>
the current three and six month periods, respectively, compared to 88%
and 84% for the corresponding periods in the prior year. These products
were sold either under contract manufacturing agreements or by FPC to its
customers in the USA. The majority of the remainder of the net sales
comprises products licensed from F H Faulding & Co. Limited, the beneficial
majority stockholder of the Company ("F H Faulding"). Net sales in the
current three and six month periods included mitomycin, which sales commenced
in the quarter ended March 31, 1996. The net sales decline in the current
quarter was principally due to a reduction of sales under the contract
manufacturing agreements most of which is caused by timing of customer orders
and lack of availability of one key raw material, since received.
Gross (loss) profit for the three and six month periods ended December 31,
1996 were ($521) and ($962), respectively, compared with $704 and $45 for
the corresponding 1995 periods. The principal cause of the reduction in
gross profit for the current periods versus the prior year's periods was the
lower contract manufacturing volume and price erosion on some of the product
line. Gross profit was unfavorably impacted in both periods by under
utilization of the production facility in Puerto Rico.
Selling, general and administrative expenses for the current three and six
month periods were $572 and $1,165, respectively, compared with the
corresponding prior period's expenses of $671 and $1,268. The expense
represent principally selling expenses associated with FPC.
Research and development expenses for the current three and six month periods
were $317 and $861, respectively, compared with $267 and $547 for the
corresponding 1995 periods. The increase in expenses was due to all three
Acquired Companies increasing development expenditures.
The loss before income taxes for the current three and six month periods
were $1,410 and $2,988, respectively, compared with a loss of $449 and
$2,223 for the corresponding 1995 periods. The reduction versus last year
is mostly due to the reduced contract manufacturing sales recorded by FPR.
Consolidated Income Tax Benefit
The calculation of the provision (benefit) for income taxes of the Company,
which includes Purepac and the Acquired Companies, has been prepared in
accordance with accounting for the acquisitions as similar to a pooling of
interests consistently applying Statement of Financial Accounting Standard
No. 109 ("SFAS 109").
For the current three and six month periods ended December 31, 1996, the
consolidated income before income taxes were $153 and $187, respectively. In
the first fiscal quarter, due to permanent tax differences which reduced the
13
<PAGE>
the taxable income to breakeven, no consolidated provision was required to
be provided.
For the Acquired Companies, only the net loss before income tax since
acquisition can be consolidated into the Company's income tax returns. The
income tax benefit of the net losses prior to acquisition have been fully
reserved against as the recovery of these losses is dependent on future
taxable income of each of the respective companies, which at present cannot
be assured.
Financial Condition, Liquidity And Capital Resources
The Company had $3,007 in cash and cash equivalents at December 31, 1996,
compared with $1,897 at June 30, 1996. The increase in the current six
month period of $1,110 resulted primarily from $7,000 borrowed from a bank
offset by $1,901 used for operating activities and $3,989 used for
investments in property, plant and equipment.
A comparison of the balance sheet accounts at December 31, 1996 to the June
30, 1996 balances shows the following to be noteworthy:
Accounts receivable decreased by $2,501 due to improved collections of
sales.
Inventory increased by $1,921 due primarily to purchases of materials
for products planned to be launched in 1997.
Net property, plant and equipment increased by $2,257 reflecting
primarily the construction of an injectable shell glass vial filling
facility in Aquadilla, Puerto Rico.
The accrued preferred dividends payable to the Company's majority
stockholder, Faulding Holdings Inc., of $689 for the three month period
ended December 31, 1996 were subsequently paid on January 2, 1997.
The Company believes that its current cash resources, anticipated operating
cash flows and funds available under a revolving credit and loan arrangement
with a bank will be sufficient to fund its working capital needs for the
next 24 months. In addition, it is not anticipated that the Acquired
Companies will generate adequate revenues to finance their combined
operating expenses until at least 1998. Beyond 1998, depending upon the
timing of the Company's cash flow requirements, which is highly dependent
upon the unpredictable timing of the receipt of FDA product approvals, the
future cash flow needs of the Company could exceed the Company's current cash
resources and its available credit under its existing credit facilities.
As of December 31, 1996, the Company had $3,007 in cash and cash equivalents,
plus approximately $8,000 of available borrowings under its existing credit
facilities.
14
<PAGE>
The Company is currently negotiating expanded credit facilities which it
anticipates will be successful. In the future, should the Company require
additional cash flow to support the commercialization of new products
following receipt of FDA approval, there can be no assurance that such
financing will be available when required, if at all, or will be available
upon terms the Company may deem commercially reasonable.
PART II - OTHER INFORMATION
Item 1. LEGAL PROCEEDINGS
On August 23, 1996, an action was commenced against the Company, Purepac,
F H Faulding and Zeneca Inc. in the United States District Court for the
District of Delaware entitled Purdue Pharma L.P. and the Purdue Frederick
Company v. F. H. Faulding & Company Ltd. [sic], Faulding Inc., Purepac
Pharmaceutical Co. and Zeneca Inc. 96 Civ. 427. The complaint alleges that
the manufacture and marketing in the United States of KADIAN(TM) infringes
a patent assigned to one of the plaintiffs and constitutes unfair competitive
practices under Federal and State law. The Company, through Purepac,
manufactures KADIAN(TM) pursuant to a contract manufacturing agreement with
Faulding Services Inc., a wholly-owned subsidiary of Faulding Holdings Inc.
The complaint seeks, among other things, an order enjoining the Company from
infringing the subject patent and awarding treble and punitive damages. The
Company believes the allegations in the complaint to be entirely without
merit and intends, in cooperation with its co-defendants, to vigorously
defend this action. The commencement of the action did not impact the
launch of KADIAN(TM).
On February 3, 1997, following the submission by Purepac of an ANDA seeking
FDA approval of Diltiazem Hydrochloride Extended-Release Capsules, USP, the
Company's proposed generic version of Cardizem-CD(R), a lawsuit was commenced
in the US District Court for the District of New Jersey under the caption
Hoechst Marion Roussel, Inc. and Carderm Capital L.P. v. Faulding Inc. and
Purepac Pharmaceutical Co., Civil Action No. 97-516(JAG Jr.), alleging that
the Company's proposed generic product infringes a patent assigned to Carderm
Capital L.P. and licensed, on a non-exclusive basis, to Hoechst Marion
Roussel, Inc., and seeking to delay the commercial introduction of the
Company's proposed generic product until the expiration of that patent.
Cardizem CD(R), which is manufactured and marketed by Hoechst Marion Roussel,
Inc., is indicated for the treatment of hypertension and for the management
of chronic stable angina and angina due to coronary artery spasm.
The Company believes that its proposed generic product does not infringe the
patent at issue in the lawsuit and, additionally, that the patent is invalid.
The Company therefore intends to defend the lawsuit vigorously.
15
<PAGE>
The Company is involved in litigation incidental to the conduct of its
business, in addition to the above matters, and does not believe that the
ultimate adverse resolutions of any, or all, thereof would have a material
adverse effect on its financial position, results of operations or cash
flows.
Item 2. through Item 4.
Not Applicable.
Item 5. OTHER EVENTS
Not Applicable.
Item 6 (a). EXHIBITS
Not Applicable.
Item 6 (b). REPORTS ON FORM 8-K
Not Applicable.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
FAULDING INC.
BY: /s/Richard F. Moldin February 12, 1997
-------------------------------------
Richard F. Moldin
President and Chief Executive Officer
(Principal Executive Officer)
BY: /s/Lee H. Craker February 12, 1997
-------------------------------------
Lee H. Craker
Chief Financial Officer
(Principal Accounting Officer)
16
<TABLE> <S> <C>
<ARTICLE> 5
<MULTIPLIER> 1,000
<S> <C>
<PERIOD-TYPE> 6-MOS
<FISCAL-YEAR-END> JUN-30-1997
<PERIOD-START> JUL-01-1996
<PERIOD-END> DEC-31-1996
<CASH> 3,007
<SECURITIES> 0
<RECEIVABLES> 14,617
<ALLOWANCES> 0
<INVENTORY> 28,417
<CURRENT-ASSETS> 51,906
<PP&E> 43,767
<DEPRECIATION> 0
<TOTAL-ASSETS> 101,758
<CURRENT-LIABILITIES> 19,996
<BONDS> 0
0
10
<COMMON> 151
<OTHER-SE> 81,601
<TOTAL-LIABILITY-AND-EQUITY> 101,758
<SALES> 40,814
<TOTAL-REVENUES> 40,814
<CGS> 29,692
<TOTAL-COSTS> 10,822
<OTHER-EXPENSES> 0
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> 113
<INCOME-PRETAX> 187
<INCOME-TAX> 75
<INCOME-CONTINUING> 112
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> 112
<EPS-PRIMARY> (.08)
<EPS-DILUTED> 0
</TABLE>
